This follow-up of a randomized clinical trial evaluates long-term survival in patients with gastrointestinal stromal tumors who were treated with 1 of 2 dose levels of imatinib mesylate and presents new molecular data regarding treatment outcomes.
http://ift.tt/2kqIynz
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου